Eterna Therapeutics
Yahoo Finance • last year
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transf... Full story
Yahoo Finance • last year
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications Novel engineered iPS cell line to be evaluated by Lineage for potential development of ce... Full story
Yahoo Finance • last year
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with trans... Full story
Yahoo Finance • last year
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transf... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Approach is potentially first iPS cell-derived multi-cell-type therapeutic strategy designed to mimic how the human immune system naturally fights disease Presentations to include additional advances in nucleic-acid delivery and targeted... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (N... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with trans... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies for multiple neurology indications – Entered into a sublease agreement with Bristo... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to provide patients with tran... Full story
